Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Cyclophosphamide Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy CG120

    Antineoplastics - Cyclophosphamide Products - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria

    Customize your policy alerts

    Sign up for Oscar Health Policy CG120 alerts

    Get alerted when Policy CG120 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-benefit exception review for preferred and non-preferred physician-administered cyclophosphamide products. It applies to members requesting a non-preferred product and establishes the circumstances and documentation needed for coverage.

    Policy Summary
    PayerOscar Health
    PolicyCyclophosphamide physician-administered drug exceptions
    Policy CodePolicy CG120
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionTry preferred cyclophosphamide products first when they are safe and effective, unless a listed exception applies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Preferred cyclophosphamide products
    2Non-preferred cyclophosphamide products
    7Listed exception pathways
    12 monthsMaximum authorization period

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3 months
    Shortage initial approval

    Non-Preferred Product Coverage Criteria

    Non-preferred Product Exception Criteria

    Coverage for a non-preferred product will be provided when BOTH criteria groups are met:

    Non-preferred product coverage

    • Qualifying exception

      • Treatment failure: Inadequate response or treatment failure with at least two preferred products.At least 2 preferred products
      • Shortage or unavailability: Drug shortage or unavailability of all preferred products.All preferred products
      • Contraindication: The member has a contraindication to all preferred products that would not exist or be reasonably expected to occur with the requested non-preferred product.All preferred products
      • Excipient hypersensitivity: Hypersensitivity to specific excipients precluding use of all preferred products.All preferred products
      • All preferred products

        Documented facility or treatment requirements must prevent use of all preferred products.

      • Evidence-supported preferential use: The requested therapy regimen has clinical evidence or current treatment guidelines, such as NCCN, supporting preferential use of the requested product over all preferred products.All preferred products
      • State prohibition on prerequisite trials: The request is for cancer treatment in a state prohibiting prerequisite trials under applicable regulations.Cancer treatment
    • Supporting documentation: Clinical documentation is provided to support the exception request.

      Examples include notification of drug shortage or unavailability; previous treatment history, including adverse reactions or treatment failures with preferred products when relevant; facility protocols or policies; and the specific reasons preferred products cannot be used.

    Authorization Duration

    If the prior authorization criteria are met:

    Authorization duration: The requested product may be authorized for up to 12 months.Up to 12 months

    For drug shortage or unavailability, initial approval is 3 months and may be extended based on continued documentation of the shortage or unavailability. If the shortage or unavailability resolves before the authorization period ends, the Plan may require transition to the preferred product at the next authorization period.

    Non-preferred products are not covered when used for experimental, investigational, medically unnecessary, unsupported non-FDA-approved, or unsupported off-label indications. Coverage is also excluded for doses exceeding FDA-approved labeling or clinical practice guidelines without sufficient evidence supporting safety and efficacy, uses not required to treat or manage the member’s condition, uses not aligned with generally accepted medical practice, or uses primarily for convenience.

    Use is considered not medically necessary when it is not required for treatment or management of the member’s medical condition or is not aligned with generally accepted medical practice. Non-preferred products used in these circumstances are not covered.

    Initial Exception Authorization Criteria

    Initial Exception Authorization

    Coverage for a non-preferred product requires BOTH of the following:

    Initial non-preferred product exception

    • One qualifying exception

      • Inadequate response or treatment failure with at least two preferred products.At least 2 preferred products
      • Drug shortage or unavailability of all preferred products.All preferred products
      • A contraindication to all preferred products that would not exist or be reasonably expected to occur with the requested non-preferred product.All preferred products

    Preferred Product Trial

    StepRequirementException pathways
    1Try preferred cyclophosphamide products first when they are safe and effective.A non-preferred product may be considered when there is inadequate response or treatment failure with at least two preferred products, or when all preferred products cannot be used because of shortage or unavailability, contraindication, excipient hypersensitivity, facility or treatment requirements, evidence-supported preferential use, or a state prohibition on prerequisite trials for cancer treatment.

    Covered Procedure and Drug Codes

    CPT/HCPCS Codes considered medically necessary if criteria are metHCPCSCovered
    J9071Injection, cyclophosphamide (auromedics), 5 mg
    J9072Injection, cyclophosphamide (avyxa), 5 mg
    J9073Injection, cyclophosphamide (Dr. Reddy's), 5 mg
    J9075Injection, cyclophosphamide, not otherwise specified, 5 mg
    J9074Injection, cyclophosphamide (sandoz), 5 mg
    J9076Injection, cyclophosphamide (baxter), 5 mg

    Authorization and Documentation Requirements

    Prior Authorization

    Preferred-Drug Exception Review

    Requests for a non-preferred cyclophosphamide product require review under the Plan’s Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria. The coverage review determines whether a clinical exception can be approved.

    • Non-preferred products listed in the Plan’s Medical Preferred Drug List are subject to the exception criteria.
    • Formulary or preferred products may still require clinical prior authorization review.
    Prior Authorization

    Submit by Indication

    Submit requests according to the indication. Oncology requests are reviewed by EviCore; non-oncology requests are submitted to Oscar Health through the specified authorization channels.

    • Oncology: Submit through the provider portal at evicore.com or by phone at 855-252-1118.
    • Non-oncology: Use the Oscar authorization tool at provider.hioscar.com, or submit by phone at 855-672-2755 or fax. The required form is available at hioscar.com/forms.

    Cyclophosphamide Product Coverage Context

    Cyclophosphamide is an antineoplastic drug administered under the medical benefit in multiple product formulations. Oscar maintains preferred and non-preferred physician-administered cyclophosphamide products; coverage of a non-preferred product requires exception review and depends on clinical necessity and evidence that preferred products cannot appropriately be used.

    Policy Definitions

    Compendia
    DefinitionSummaries of drug information and medical evidence used to support decision-making about the appropriate use of drugs and medical procedures.
    ExamplesAmerican Hospital Formulary Service Drug Information; Elsevier Clinical Pharmacology; National Comprehensive Cancer Network Drugs and Biologics Compendium.
    Additional examplesThomson Micromedex DrugDex and United States Pharmacopeia-National Formulary (USP-NF).
    Contraindication
    DefinitionA pre-existing condition or factor that precludes use of a drug due to risk of harm.
    TimingThe condition or factor exists before the drug is used.
    Policy Summary
    PayerOscar Health
    PolicyCyclophosphamide physician-administered drug exceptions
    Policy CodePolicy CG120
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionTry preferred cyclophosphamide products first when they are safe and effective, unless a listed exception applies.
    SourceLink
    On This Page
    Non-Preferred Product Coverage CriteriaInitial Exception Authorization CriteriaPreferred Product TrialCovered Procedure and Drug CodesAuthorization and Documentation RequirementsCyclophosphamide Product Coverage ContextPolicy Definitions
  1. Hypersensitivity to specific excipients precluding use of all preferred products.All preferred products
  2. Documented facility or treatment requirements cannot be met with all preferred products because of required concentration specifications for the route of administration or specific preparation or stability requirements.All preferred products
  3. Clinical evidence or current treatment guidelines, such as NCCN, support preferential use of the requested product over all preferred products.All preferred products
  4. The request is for cancer treatment in a state prohibiting prerequisite trials under applicable regulations.Cancer treatment
  5. Supporting clinical documentation: Clinical documentation supports the exception request.

    Examples include shortage or unavailability notifications, previous treatment history with relevant adverse reactions or treatment failures, facility protocols or policies, and the specific reasons preferred products cannot be used.

  6. Step Therapy

    Try Preferred Products First

    Preferred cyclophosphamide products generally must be tried first when they are considered safe and effective for the member. A non-preferred product may be requested when the member has tried and failed, cannot use, or is not an appropriate candidate for the preferred products under the applicable exception criteria.

    • Exceptions may include documented failure, inadequate response, intolerance, or contraindication to all applicable preferred products.
    • Other exceptions may include risk factors for poor response, individual treatment needs, accepted standards of practice, shortage or unavailability, facility requirements, supporting clinical evidence, or state regulations prohibiting prerequisite trials.
    Documentation Required

    Provide Clinical and Prior-Treatment Records

    Submit current clinical information supporting the diagnosis and treatment request, together with records showing prior treatment with alternatives.

    • Up-to-date chart notes.
    • Relevant test results and/or imaging reports.
    • Prescription claims records and/or prescription receipts supporting prior trials of alternatives.
    Documentation Required

    Document the Exception

    Provide documentation that supports why the preferred products cannot be used and why the requested non-preferred product qualifies for an exception.

    • Notification of drug shortage or unavailability.
    • Previous treatment history, including adverse reactions or treatment failures with preferred products, when relevant.
    • Facility protocols or policies, including required concentration, preparation, route, or stability requirements.
    • Specific reasons the preferred products cannot be used.
    • Clinical evidence or current treatment guidelines supporting preferential use of the requested product, when applicable.
    Documentation Required

    Document Intolerance Specifically

    When intolerance is the basis for the request, document the specific effects or reactions that made the preferred treatment intolerable and explain their impact on treatment.

    • Identify the specific intolerable side effects, reactions, or hypersensitivities.
    • Describe how they affected treatment, adherence, quality of life, ability to function, or overall health.
    Denial Risk

    Meet Exception Criteria and Documentation Requirements

    Coverage requires both a qualifying exception and clinical documentation supporting that exception. Requests may be denied when the required exception criteria or documentation are not met.

    • The member must meet at least one qualifying exception criterion, such as failure of at least two preferred products, shortage or unavailability of all preferred products, contraindication or excipient hypersensitivity affecting all preferred products, facility requirements, evidence-based preferential use, or a legally permitted exception to prerequisite trials.
    • Clinical documentation must support the qualifying exception and explain why the preferred products cannot be used.
    • If approved, authorization may be issued for up to 12 months; shortage-based initial approvals are limited to 3 months and may require continued documentation.
    Denial Risk

    Unapproved or Medically Unnecessary Use

    The Plan does not cover non-preferred products when used for experimental, investigational, unapproved, or medically unnecessary indications.

    • Non-FDA-approved or off-label use without sufficient evidence of safety and efficacy is excluded.
    • Excessive dosing or use outside accepted indications, standards of care, or generally accepted medical practice may be excluded.
    • Use not required to treat or manage the member’s condition, or primarily for the convenience of the member, family, or provider, is excluded.
    Coverage relevance
    A contraindication may support an exception when it prevents use of the preferred drug because of risk of harm.
    Intolerance
    DefinitionThe inability to tolerate or endure a medication or treatment because of difficult or harmful side effects, reactions, or hypersensitivities.
    Potential impactThe effects negatively impact quality of life, ability to adhere, or overall health.
    Required supportDocumentation is expected to detail the specific intolerable effects and their impact on treatment.
    Documentation
    DefinitionWritten information supporting a diagnosis, treatment decision, or prior trial of alternatives.
    Clinical recordsUp-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses.
    Prior-treatment recordsPrescription claims records and/or prescription receipts to support prior trials of alternatives.
    Experimental or Investigational
    DefinitionProcedures, drugs, or devices that have not been proven effective or have not been approved by the appropriate regulatory bodies.
    Evidence standardThe procedure, drug, or device must be proven effective to avoid being considered experimental or investigational.
    Approval standardThe procedure, drug, or device must be approved by the appropriate regulatory bodies.
    Medical Benefit Preferred Drug Exceptions Criteria
    DefinitionPlan requirements that must be met for a non-preferred drug to be approved for coverage.
    Preferred-drug requirementRequirements may include trying preferred drugs first.
    Failure requirementRequirements may include trial and failure of preferred drugs before approval of the non-preferred drug.